GOALS OF WORK: The objective of this study was to evaluate the safety and tolerability of velafermin in patients at risk of developing severe oral mucositis (OM) from chemotherapy. MATERIALS AND METHODS: This study was a single-center, open-label, single-dose escalation, phase I trial in patients undergoing high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplant (PBSCT). Velafermin was administered 24 h after stem cell infusion as a single intravenous dose infused over 15 min. Clinical safety variables were assessed and OM status scored daily for 30 days using the World Health Organization (WHO) grading scale. MAIN RESULTS: Thirty patients were treated with velafermin at doses of 0.03 (n = 10), 0.1 (n = 10), 0.2 (n = 8), or 0.33 mg/kg (n = 2). Patients were diagnosed with multiple myeloma (n = 16), non-Hodgkin's lymphoma (n = 12), acute myelogenous leukemia (n = 1), or desmoplasmic round cell tumor (n = 1). Velafermin was well tolerated at doses up to 0.2 mg/kg. There were no drug-related serious adverse events. No patient discontinued because of adverse events; however, two patients administered 0.33 mg/kg developed adverse reactions immediately after infusion of the study drug. No other patients were treated at this dose level. The most frequent (>35% of patients) treatment-emergent adverse events were diarrhea, fatigue, pyrexia, vomiting, and nausea. Most adverse events were mild or moderate and resolved the same day without sequelae. Eight (27%) patients developed WHO grade 3 or 4 OM during the study; seven of these patients received high-dose melphalan as a conditioning regimen. CONCLUSION: Velafermin was well tolerated by autologous PBSCT patients at doses up to 0.2 mg/kg.
GOALS OF WORK: The objective of this study was to evaluate the safety and tolerability of velafermin in patients at risk of developing severe oral mucositis (OM) from chemotherapy. MATERIALS AND METHODS: This study was a single-center, open-label, single-dose escalation, phase I trial in patients undergoing high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplant (PBSCT). Velafermin was administered 24 h after stem cell infusion as a single intravenous dose infused over 15 min. Clinical safety variables were assessed and OM status scored daily for 30 days using the World Health Organization (WHO) grading scale. MAIN RESULTS: Thirty patients were treated with velafermin at doses of 0.03 (n = 10), 0.1 (n = 10), 0.2 (n = 8), or 0.33 mg/kg (n = 2). Patients were diagnosed with multiple myeloma (n = 16), non-Hodgkin's lymphoma (n = 12), acute myelogenous leukemia (n = 1), or desmoplasmic round cell tumor (n = 1). Velafermin was well tolerated at doses up to 0.2 mg/kg. There were no drug-related serious adverse events. No patient discontinued because of adverse events; however, two patients administered 0.33 mg/kg developed adverse reactions immediately after infusion of the study drug. No other patients were treated at this dose level. The most frequent (>35% of patients) treatment-emergent adverse events were diarrhea, fatigue, pyrexia, vomiting, and nausea. Most adverse events were mild or moderate and resolved the same day without sequelae. Eight (27%) patients developed WHO grade 3 or 4 OM during the study; seven of these patients received high-dose melphalan as a conditioning regimen. CONCLUSION: Velafermin was well tolerated by autologous PBSCT patients at doses up to 0.2 mg/kg.
Authors: Enrique Alvarez; Edward G Fey; Pascal Valax; Zachary Yim; Jeffrey D Peterson; Medhi Mesri; Michael Jeffers; Matthew Dindinger; Nancy Twomlow; Ashwini Ghatpande; William J LaRochelle; Stephen T Sonis; Henri S Lichenstein Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: Mario N Chamorro; Donald R Schwartz; Alin Vonica; Ali H Brivanlou; Kathleen R Cho; Harold E Varmus Journal: EMBO J Date: 2004-12-09 Impact factor: 11.598
Authors: A Spencer; N Horvath; J Gibson; H M Prince; R Herrmann; J Bashford; D Joske; A Grigg; J McKendrick; I Prosser; R Lowenthal; S Deveridge; K Taylor Journal: Bone Marrow Transplant Date: 2005-05 Impact factor: 5.483
Authors: M A Stokman; F M Wachters; P Koopmans; J G M Burgerhof; H J M Groen; F K L Spijkervet; D R A Uges; G A P Hospers Journal: Anticancer Res Date: 2004 Sep-Oct Impact factor: 2.480
Authors: Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Enrique Alvarez; Valerie L Gerlach; Robert W Gerwien; Edward G Fey; Brynmor A Watkins; William F Hahne; Stephen T Sonis Journal: Support Cancer Ther Date: 2005-01-01
Authors: Michael Jeffers; William F McDonald; Rajeev A Chillakuru; Meijia Yang; Hiroshi Nakase; Lisa L Deegler; Elizabeth D Sylander; Beth Rittman; Alison Bendele; R Balfour Sartor; Henri S Lichenstein Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid Journal: Cochrane Database Syst Rev Date: 2011-04-13
Authors: Judith E Raber-Durlacher; Inger von Bültzingslöwen; Richard M Logan; Joanne Bowen; Abdul Rahman Al-Azri; Hele Everaus; Erich Gerber; Jesùs Garcia Gomez; Bo G Pettersson; Yoshihiko Soga; Fred K L Spijkervet; Wim J E Tissing; Joel B Epstein; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2012-09-18 Impact factor: 3.603
Authors: Richard M Logan; Abdul Rahman Al-Azri; Paolo Bossi; Andrea M Stringer; Jamie K Joy; Yoshihiko Soga; Vinisha Ranna; Anusha Vaddi; Judith E Raber-Durlacher; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2020-02-21 Impact factor: 3.603